Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linzee Mabrey

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Ebiomedicine|June 19, 2023
Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumoniaF Linzee Mabrey, Hui Nian, Chang Yu, et al.
Blood Advances|February 20, 2020
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndromeFrances Linzee Mabrey, Kelda M Gardner, Kathleen Shannon Dorcy, et al.
The Lancet. Respiratory Medicine|May 15, 2026
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, studyD Clark Files, Michael A Matthay, Andrew G Chapple, et al.
American Journal of Respiratory Cell and Molecular Biology|July 1, 2024
PD-L1 and PD-1 Are Associated with Clinical Outcomes and Alveolar Immune Cell Activation in Acute Respiratory Distress SyndromeEric D Morrell, Sarah E Holton, Alice Wiedeman, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 24, 2022
Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illnessEric D Morrell, Pavan K Bhatraju, Neha A Sathe, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Ebiomedicine|June 19, 2023
Phase 2, randomized, double-blind, placebo-controlled multi-center trial of the clinical and biological effects of anti-CD14 treatment in hospitalized patients with COVID-19 pneumoniaF Linzee Mabrey, Hui Nian, Chang Yu, et al.
Blood Advances|February 20, 2020
Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndromeFrances Linzee Mabrey, Kelda M Gardner, Kathleen Shannon Dorcy, et al.
The Lancet. Respiratory Medicine|May 15, 2026
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, studyD Clark Files, Michael A Matthay, Andrew G Chapple, et al.
American Journal of Respiratory Cell and Molecular Biology|July 1, 2024
PD-L1 and PD-1 Are Associated with Clinical Outcomes and Alveolar Immune Cell Activation in Acute Respiratory Distress SyndromeEric D Morrell, Sarah E Holton, Alice Wiedeman, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 24, 2022
Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illnessEric D Morrell, Pavan K Bhatraju, Neha A Sathe, et al.
Pageof 2